Androgen receptor molecular biology and potential targets in prostate cancer

Therapeutic Advances in Urology

Volumn 2, Issue 3, 2010, Pages 105-117

  Wilson, Elizabeth M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

androgen receptor; cancer'testis antigens; MAGE 11; MAGE A11; N C interaction; X chromosome; X linked genes

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; BORTEZOMIB; CANCER TESTIS ANTIGEN; CANCER VACCINE; MELANOMA ANTIGEN; MELANOMA ANTIGEN GENE PROTEIN A11; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; CANCER GROWTH; CANCER RECURRENCE; CASTRATION; CHROMOSOME XQ; CHROMOSOME XQ28; DRUG TARGETING; GENE ACTIVATION; GENETIC TRANSCRIPTION; HUMAN; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TESTIS; X CHROMOSOME;

EID: 79551703479     PISSN: 17562872     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756287210372380     Document Type: Article

References (128)

1. Akaza, H., Hinotsu, S., Usami, M., Arai, Y., Kanetake, H., Naito, S. et al. (2009) Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 115: 3437-3445.
2. Almeida, L.G., Sakabe, N.J., deOliveira, A.R., Silva, M.C., Mundstein, A.S., Cohen, T. et al. (2009) CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res 37: D816-D819.
3. Andrade, V.C., Vettore, A.L., Felix, R.S., Almeida, M.S., Carvalho, F., Oliveira, J.S. et al. (2008) Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. Cancer Immun 8: 2.
4. Aprelikova, O., Pandolfi, S., Tackett, S., Ferreira, M., Salnikow, K., Ward, Y. et al. (2009) Melanoma antigen-11 inhibits the hypoxia-inducible factor prolyl hydroxylase 2 and activates hypoxic response. Cancer Res 69: 616-624.
5. Arkin, M.R. and Wells, J.A. (2004) Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 3: 301-317.
6. Artamonova, I.I. and Gelfand, M.S. (2004) Evolution of the exon-intron structure and alternative splicing of the MAGE-A family of cancer/testis antigens. J Mol Evol 59: 620-631.
7. Askew, E.B., Bai, S., Blackwelder, A.J. and Wilson, E.M. (2010) Transcriptional synergy between melanoma antigen gene protein-A11 (MAGE-11) and p300 in androgen receptor signaling. J Biol Chem [Epub ahead of print].
8. Askew, E.B., Bai, S., Hnat, A.T., Minges, J.T. and Wilson, E.M. (2009) Melanoma antigen gene protein-A11 (MAGE-11) F-box links the androgen receptor NH2-terminal transactivation domain to p160 coactivators. J Biol Chem 284: 34793-34808.
9. Askew, E.B., Gampe, R.T., Stanley, T.B., Faggart, J.L. and Wilson, E.M. (2007) Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. J Biol Chem 282: 25801-25816.
10. Atanackovic, D., Altorki, N.K., Cao, Y., Ritter, E., Ferrara, C.A., Ritter, G. et al. (2008) Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci U S A 105: 1650-1655.
11. Attard, G., Reid, A.H., Olmos, D. and de Bono, J.S. (2009) Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 69: 4937-4940.
12. Baertsch, R., Diekhans, M., Kent, W.J., Haussler, D. and Brosius, J. (2008) Retrocopy contributions to the evolution of the human genome. BMC Genomics 9: 466.
13. Bai, S., Grossman, G., Yuan, L., Lessey, B.A., French, F.S., Young, S.L. et al. (2008) Hormone control and expression of androgen receptor coregulator MAGE-11 in human endometrium during the window of receptivity to embryo implantation. Mol Hum Reproduction 14: 107-116.
14. Bai, S., He, B. and Wilson, E.M. (2005) Melanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interaction. Mol Cell Biol 25: 1238-1257.
15. Bai, S. and Wilson, E.M. (2008) Epidermal growth factor-dependent phosphorylation and ubiquitinylation of MAGE-11 regulates its interaction with the androgen receptor. Mol Cell Biol 28: 1947-1963.
16. Barker, P.A. and Salehi, A. (2002) The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease. J Neurosci Res 67: 705-712.
17. Bender, A., Karbach, J., Neumann, A., Jäger, D., Al-Batran, S.E., Atmaca, A. et al. (2007) LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. Cancer Immun 7: 16.
18. Berra, E., Benizri, E., Ginouvès, A., Volmat, V., Roux, D. and Pouysségur, J. (2003) HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 22: 4082-4090.
19. Boccaccio, I., Glatt-Deeley, H., Watrin, F., Roëckel, N., Lalande, M. and Muscatelli, F. (1999) The human MAGEL2 gene and its mouse homologue are paternally expressed and mapped to the Prader-Willi region. Hum Mol Genet 8: 2497-2505.
20. Brooke, G.N. and Bevan, C.L. (2009) The role of androgen receptor mutations in prostate cancer progression. Curr Genomics 10: 18-25.
21. Brown, C.J., Goss, S.J., Lubahn, D.B., Joseph, D.R., Wilson, E.M., French, F.S. et al. (1989) Androgen receptor locus on the human X chromosome: regional localization to Xq11-12 and description of a DNA polymorphism. Am J Hum Genet 44: 264-269.
22. Brown, T.R. (1995) Human androgen insensitivity syndrome. J Androl 16: 299-303.
23. Brown, W.M., Lange, E.M., Chen, H., Zheng, S.L., Chang, B., Wiley, K.E. et al. (2004) Hereditary prostate cancer in African American families: linkage analysis using markers that map to five candidate susceptibility loci. Br J Cancer 90: 510-514.
24. Carroll, J.S., Meyer, C.A., Song, J., Li, W., Geistlinger, T.R., Eeckhoute, J. et al. (2006) Genome-wide analysis of estrogen receptor binding sites. Nat Genet 38: 1289-1297.
25. Cha, E. and Fong, L. (2010) Therapeutic vaccines for prostate cancer. Curr Opin Mol Ther 12: 77-85.
26. Chang, C.Y., Walther, P.J. and McDonnell, D.P. (2001) Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer. Cancer Res 61: 8712-8717.
27. Chen, T., Kablaoui, N., Little, J., Timofeevski, S., Tschantz, W.R., Chen, P. et al. (2009) Identification of small molecule inhibitors of the JIP and JNK interaction. Biochem J 420: 283-294.
28. Chi, K.N., Bjartell, A., Dearnaley, D., Saad, F., Schröder, F.H., Sternberg, C. et al. (2009) Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol 56: 594-605.
29. Chomez, P., De Backer, O., Bertrand, M., De Plaen, E., Boon, T. and Lucas, S. (2001) An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 61: 5544-5551.
30. Culig, Z. and Bartsch, G. (2006) Androgen axis in prostate cancer. J Cell Biochem 99: 373-381.
31. Culig, Z., Steiner, H., Bartsch, G. and Hobisch, A. (2005) Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 95: 497-505.
32. Delbridge, M.L. and Graves, J.A. (2007) Origin and evolution of spermatogenesis genes on the human sex chromosomes. Soc Reprod Fertil Suppl 65: 1-17.
33. De Plaen, E., Arden, K., Traversari, C., Gaforio, J.J., Szikora, J.P., De Smet, C. et al. (1994) Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 40: 360-369.
34. De Plaen, E., De Backer, O., Arnaud, D., Bonjean, B., Chomez, P., Martelange, V. et al. (1999) A new family of mouse genes homologous to the human MAGE genes. Genomics 55: 176-184.
35. De Smet, C., De Backer, O., Faraoni, I., Lurquin, C., Brasseur, F. and Boon, T. (1996) The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci U S A 93: 7149-7153.
36. De Smet, C., Loriot, A. and Boon, T. (2004) Promoter-dependent mechanism leading to selective hypomethylation within the 5’ region of gene MAGE-A1 in tumor cells. Mol Cell Biol 24: 4781-4790.
37. De Smet, C., Lurquin, C., Lethé, B., Martelange, V. and Boon, T. (1999) DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 19: 7327-7335.
38. Dobosy, J.R., Roberts, J.L., Fu, V.X. and Jarrard, D.F. (2007) The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J Urol 177: 822-831.
39. Dutt, S.S. and Gao, A.C. (2009) Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol 5: 1403-1413.
40. Ehrlich, M. (2002) DNA methylation in cancer: too much, but also too little. Oncogene 21: 5400-5413.
41. Furutani, T., Takeyama, K., Koutoku, H., Ito, S., Taniguchi, N., Suzuki, E. et al. (2005) A role of androgen receptor protein in cell growth of an androgen-independent prostate cancer cell line. Biosci Biotechnol Biochem 69: 2236-2239.
42. Gaugler, B., Van den Eynde, B., van der Bruggen, P., Romero, P., Gaforio, J.J., De Plaen, E. et al. (1994) Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179: 921-930.
43. Golias, C., Iliadis, I., Peschos, D. and Charalabopoulos, K. (2009) Amplification and co-regulators of androgen receptor gene in prostate cancer. Exp Oncol 31: 3-8.
44. Graat, H.C., Carette, J.E., Schagen, F.H., Vassilev, L.T., Gerritsen, W.R., Kaspers, G.J. et al. (2007) Enhanced tumor cell kill by combined treatment with a small-molecule antagonist of mouse double minute 2 and adenoviruses encoding p53. Mol Cancer Ther 6: 1552-1561.
45. Gregory, C.W., Fei, X., Ponguta, L.A., He, B., Bill, H.M., French, F.S. and Wilson, E.M. (2004) Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem 279: 7119-7130.
46. Gregory, C.W., He, B., Johnson, R.T., Ford, O.H., Mohler, J.L., French, F.S. and Wilson, E.M. (2001) A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61: 4315-4319.
47. Gregory, C.W., Johnson, R.T., Mohler, J.L., French, F.S. and Wilson, E.M. (2001) Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61: 2892-2898.
48. Grigoriadis, A., Caballero, O.L., Hoek, K.S., da Silva, L., Chen, Y.T., Shin, S.J. et al. (2009) CT-X antigen expression in human breast cancer. Proc Natl Acad Sci U S A 106: 13493-13498.
49. Guo, Z., Dai, B., Jiang, T., Xu, K., Xie, Y., Kim, O. et al. (2006) Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 10: 309-319.
50. Gure, A.O., Chua, R., Williamson, B., Gonen, M., Ferrera, C.A., Gnjatic, S. et al. (2005) Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 11: 8055-8062.
51. Harris, S.E., Harris, M.A., Rong, Z., Hall, J., Judge, S., French, F.S. et al. (1991) Androgen regulation of HBGF-1 (alpha FGF) mRNA and characterization of the androgen receptor mRNA in the human prostate carcinoma cell line LNCaP/A-Dep, In: Karr, J.P., Coffey, D.S., Smith, R.G. and Tindall, D.J. (eds). Molecular and Cellular Biology of Prostate Cancer, Plenum Press: New York, pp. 315-330.
52. He, B., Bowen, N.T., Minges, J.T. and Wilson, E.M. (2001) Androgen-induced NH2- and carboxyl-terminal interaction inhibits p160 coactivator recruitment by activation function 2. J Biol Chem 276: 42293-42301.
53. He, B., Gampe, R.T., Hnat, A.T., Faggart, J.L., Minges, J.T., French, F.S. and Wilson, E.M. (2006) Probing the functional link between androgen receptor coactivator and ligand binding sites in prostate cancer and androgen insensitivity. J Biol Chem 281: 6648-6663.
54. He, B., Gampe, R.T., Kole, A.J., Hnat, A.T., Stanley, T.B., An, G. et al. (2004) Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol Cell 16: 425-438.
55. He, B., Kemppainen, J.A. and Wilson, E.M. (2000) FXXLF and WXXLF sequences mediate the NH2terminal interaction with the ligand binding domain of the androgen receptor. J Biol Chem 275: 22986-22994.
56. He, B., Lee, L.W., Minges, J.T. and Wilson, E.M. (2002) Dependence of selective gene activation on the androgen receptor NH2- and carboxyl-terminal interaction. J Biol Chem 277: 25631-25639.
57. Heemers, H.V. and Tindall, D.J. (2007) Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 28: 778-808.
58. Hérin, M., Lemoine, C., Weynants, P., Vessière, F., Van Pel, A., Knuth, A. et al. (1987) Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int J Cancer 39: 390-396.
59. Hieronymus, H., Lamb, J., Ross, K.N., Peng, X.P., Clement, C., Rodina, A. et al. (2006) Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 10: 321-330.
60. Hong, J.A., Kang, Y., Abdullaev, Z., Flanagan, P.T., Pack, S.D., Fischette, M.R. et al. (2005) Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res 65: 7763-7774.
61. Irvine, R.A. and Coetzee, G.A. (1999) Additional upstream coding sequences of MAGE-11. Immunogenetics 49: 585.
62. Jurk, M., Kremmer, E., Schwarz, U., Förster, R. and Winnacker, E.L. (1998) MAGE-11 protein is highly conserved in higher organisms and located predominantly in the nucleus. Int J Cancer 75: 762-766.
63. Kalejs, M. and Erenpreisa, J. (2005) Cancer/testis antigens and gametogenesis: a review and ‘‘brainstorming–– session. Cancer Cell Int 5: 4.
64. Karpf, A.R. (2006) A potential role for epigenetic modulatory drugs in the enhancement of cancer/ germ-line antigen vaccine efficacy. Epigenetics 1: 116-120.
65. Karpf, A.R., Bai, S., James, S.R., Mohler, J.L. and Wilson, E.M. (2009) Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP. Mol Cancer Res 7: 523-535.
66. Kemppainen, J.A., Langley, E., Wong, C.I., Bobseine, K., Kelce, W.R. and Wilson, E.M. (1999) Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Mol Endocrinol 13: 440-454.
67. Klein, K.A., Reiter, R.E., Redula, J., Moradi, H., Zhu, X.L., Brothman, A.R. et al. (1997) Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 3: 402-408.
68. Knudsen, K.E. and Penning, T.M. (2010) Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab 21: 315-324.
69. Kolb-Kokocinski, A., Mehrle, A., Bechtel, S., Simpson, J.C., Kioschis, P., Wiemann, S. et al. (2006) The systematic functional characterisation of Xq28 genes prioritises candidate disease genes. BMC Genomics 7: 29.
70. Lassie, K. and Dawson, N.A. (2010) Update on castrate-resistant prostate cancer: 2010. Curr Opin Oncol 22: 263-267.
71. Lee, S., Walker, C.L., Karten, B., Kuny, S.L., Tennese, A.A., O–Neill, M.A. and Wevrick, R. (2005) Essential role for the Prader-Willi syndrome protein necdin in axonal outgrowth. Hum Mol Genet 14: 627-637.
72. Li, T.H., Zhao, H., Peng, Y., Beliakoff, J., Brooks, J.D. and Sun, Z.A. (2007) A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells. Nucleic Acids Res 35: 2767-2776.
73. Linja, M.J., Savinainen, K.J., Saramäki, O.R., Tammela, T.L., Vessella, R.L. and Visakorpi, T. (2001) Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61: 3550-3555.
74. Locke, J.A., Guns, E.S., Lubik, A.A., Adomat, H.H., Hendy, S.C., Wood, C.A. et al. (2008) Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 68: 6407-6415.
75. Loukinov, D.I., Pugacheva, E., Vatolin, S., Pack, S.D., Moon, H., Chernukhin, I. et al. (2002) BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc Natl Acad Sci U S A 99: 6806-6811.
76. Mao, C., Patterson, N.M., Cherian, M.T., Aninye, I.O., Montoya, J.B., Zhang, C. et al. (2008) A new small molecule inhibitor of estrogen receptor alpha binding to estrogen response elements blocks estrogen-dependent growth of cancer cells. J Biol Chem 283: 12819-12830.
77. Marchand, M., Punt, C.J., Aamdal, S., Escudier, B., Kruit, W.H., Keilholz, U. et al. (2003) Immunization of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 39: 70-77.
78. Matsumoto, K., Taniura, H., Uetsuki, T. and Yoshikawa, K. (2001) Necdin acts as a transcriptional repressor that interacts with multiple guanosine clusters. Gene 272: 173-179.
79. Mellinghoff, I.K., Vivanco, I., Kwon, A., Tran, C., Wongvipat, J. and Sawyers, C.L. (2004) HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6: 517-527.
80. Mischo, A., Kubuschok, B., Ertan, K., Preuss, K.D., Romeike, B., Regitz, E. et al. (2006) Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer. Int J Cancer 118: 696-703.
81. Mohler, J.L., Gregory, C.W., Ford, O.H., Kim, D., Weaver, C.M., Petrusz, P. et al. (2004) The androgen axis in recurrent prostate cancer. Clin Can Res 10: 440-448.
82. Monte, M., Simonatto, M., Peche, L.Y., Bublik, D.R., Gobessi, S., Pierotti, M.A. et al. (2006) MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci U S A 103: 11160-11165.
83. Montgomery, R.B., Mostaghel, E.A., Vessella, R., Hess, D.L., Kalhorn, T.F., Higano, C.S. et al. (2008) Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68: 4447-4454.
84. Napoletano, C., Bellati, F., Tarquini, E., Tomao, F., Taurino, F., Spagnoli, G. et al. (2008) MAGE-A and NY-ESO-1 expression in cervical cancer: prognostic factors and effects of chemotherapy. Am J Obstet Gynecol 198: 99.e1-7.
85. Odunsi, K., Qian, F., Matsuzaki, J., Mhawech-Fauceglia, P., Andrews, C., Hoffman, E.W. et al. (2007) Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A 104: 12837-12842.
86. Ohman Forslund, K. and Nordqvist, K. (2001) The melanoma antigen genes-any clues to their functions in normal tissues? Exp Cell Res 265: 185-194.
87. O–Malley, B.W. (2009) The year in basic science: nuclear receptors and coregulators. Mol Endocrinol 22: 2751-2758.
88. Park, J.H. and Lee, S.W. (2002) Hypertonicity induction of melanoma antigen, a tumor-associated antigen. Mol Cells 13: 288-295.
89. Ponguta, L.A., Gregory, C.W., French, F.S. and Wilson, E.M. (2008) Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-recurrent prostate cancer. J Biol Chem 283: 20989-21001.
90. Quigley, C.A., De Bellis, A., Marschke, K.B., El-Awady, M.K., Wilson, E.M. and French, F.S. (1995) Androgen receptor defects: historical, clinical and molecular perspectives. Endocrine Rev 16: 271-321.
91. Reid, A.H., Attard, G., Danila, D.C., Oommen, N.B., Olmos, D., Fong, P.C. et al. (2010) Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the cyp17 inhibitor abiraterone acetate. J Clin Oncol 28: 1489-1495.
92. Rogner, U.C., Wilke, K., Steck, E., Korn, B. and Poustka, A. (1995) The melanoma antigen gene (MAGE) family is clustered in the chromosomal band Xq28. Genomics 29: 725-731.
93. Ross, M.T., Grafham, D.V., Coffey, A.J., Scherer, S., McLay, K., Muzny, D. et al. (2005) The DNA sequence of the human X chromosome. Nature 434: 325-337.
94. Sadanaga, N., Nagashima, H., Mashino, K., Tahara, K., Yamaguchi, H., Ohta, M. et al. (2001) Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 7: 2277-2284.
95. Saifi, G.M. and Chandra, H.S. (1999) An apparent excess of sex- and reproduction-related genes on the human X chromosome. Proc Biol Sci 266: 203-209.
96. Salehi, A.H., Roux, P.P., Kubu, C.J., Zeindler, C., Bhakar, A., Tannis, L.L. et al. (2000) NRAGE, a novel MAGE protein, interacts with the p75 neurotrophin receptor and facilitates nerve growth factor-dependent apoptosis. Neuron 27: 279-288.
97. Scanlan, M.J., Gure, A.O., Jungbluth, A.A., Old, L.J. and Chen, Y.T. (2002) Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 188: 22-32.
98. Scanlan, M.J., Simpson, A.J. and Old, L.J. (2004) The cancer/testis genes: review, standardization, and commentary. Cancer Immun 4: 1.
99. Schmitt, B., Wilt, T.J., Schellhammer, P.F., DeMasi, V., Sartor, O., Crawford, E.D. and Bennett, C.L. (2001) Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology 57: 727-732.
100. Schulz, W.A. and Hoffmann, M.J. (2009) Epigenetic mechanisms in the biology of prostate cancer. Semin Cancer Biol 19: 172-180.
101. Shichijo, S., Yamada, A., Sagawa, K., Iwamoto, O., Sakata, M., Nagai, K. and Itoh, K. (1996) Induction of MAGE genes in lymphoid cells by the demethylating agent 5-aza-2’-deoxycytidine. Jpn J Cancer Res 87: 751-756.
102. Simpson, A.J., Caballero, O.L., Jungbluth, A., Chen, Y.T. and Old, L.J. (2005) Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5: 615-625.
103. Solit, D.B., Scher, H.I. and Rosen, N. (2003) Hsp90 as a therapeutic target in prostate cancer. Semin Oncol 30: 709-716.
104. Stanbrough, M., Bubley, G.J., Ross, K., Golub, T.R., Rubin, M.A., Penning, T.M. et al. (2006) Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66: 2815-2825.
105. Stavridi, F., Karapanagiotou, E.M. and Syrigos, K.N. (2010) Targeted therapeutic approaches for hormone-refractory prostate cancer. Cancer Treat Rev 36: 122-130.
106. Stephan, D.A., Howell, G.R., Teslovich, T.M., Coffey, A.J., Smith, L., Bailey-Wilson, J.E. et al. (2002) Physical and transcript map of the hereditary prostate cancer region at xq27. Genomics 79: 41-50.
107. Tan, J., Sharief, Y., Hamil, K.G., Gregory, C.W., Zang, D.Y., Sar, M. et al. (1997) Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 11: 450-459.
108. Taniura, H., Kobayashi, M. and Yoshikawa, K. (2005) Functional domains of necdin for protein-protein interaction, nuclear matrix targeting, and cell growth suppression. J Cell Biochem 94: 804-815.
109. Taniura, H., Matsumoto, K. and Yoshikawa, K. (1999) Physical and functional interactions of neuronal growth suppressor necdin with p53. J Biol Chem 274: 16242-16248.
110. Tay, S.K., Blythe, J. and Lipovich, L. (2009) Global discovery of primate-specific genes in the human genome. Proc Natl Acad Sci U S A 106: 12019-12024.
111. Thurner, B., Haendle, I., Röder, C., Dieckmann, D., Keikavoussi, P., Jonuleit, H. et al. (1999) Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190: 1669-1678.
112. Titus, M.A., Gregory, C.W., Ford, O.H., Schell, M.J., Maygarden, S.J. and Mohler, J.L. (2005a) Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 11: 4365-4371.
113. Titus, M.A., Schell, M.J., Lih, F.B., Tomer, K.B. and Mohler, J.L. (2005b) Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11: 4653-4657.
114. Turner, L.M. and Hoekstra, H.E. (2008) Causes and consequences of the evolution of reproductive proteins. Int J Dev Biol 52: 769-780.
115. Velazquez, E.F., Jungbluth, A.A., Yancovitz, M., Gnjatic, S., Adams, S., O–Neill, D. et al. (2007) Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)-correlation with prognostic factors. Cancer Immun 7: 11.
116. Veldscholte, J., Ris-Stalpers, C., Kuiper, G.G., Jenster, G., Berrevoets, C., Claassen, E. et al. (1990) A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173: 534-540.
117. Vis, A.N. and Schröder, F.H. (2009) Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways. BJU Int 104: 438-448.
118. Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C. et al. (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9: 401-406.
119. Waltering, K.K., Helenius, M.A., Sahu, B., Manni, V., Linja, M.J., Jänne, O.A. and Visakorpi, T. (2009) Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 69: 8141-8149.
120. Wang, G.L., Jiang, B.H., Rue, E.A. and Semenza, G.L. (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 92: 5510-5514.
121. Wen, C.J., Xue, B., Qin, W.X., Yu, M., Zhang, M.Y., Zhao, D.H. et al. (2004) hNRAGE, a human neurotrophin receptor interacting MAGE homologue, regulates p53 transcriptional activity and inhibits cell proliferation. FEBS Lett 564: 171-176.
122. Wischnewski, F., Friese, O., Pantel, K. and Schwarzenbach, H. (2007) Methyl-CpG binding domain proteins and their involvement in the regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 gene promoters. Mol Cancer Res 5: 749-759.
123. Wischnewski, F., Pantel, K. and Schwarzenbach, H. (2006) Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1-A2-A3, and -A12 in human cancer cells. Mol Cancer Res 4: 339-349.
124. Xu, J., Meyers, D., Freije, D., Isaacs, S., Wiley, K., Nusskern, D. et al. (1998) Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 20: 175-179.
125. Yang, B., O–Herrin, S.M., Wu, J., Reagan-Shaw, S., Ma, Y., Bhat, K.M. et al. (2007) MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGEpositive cell lines. Cancer Res 67: 9954-9962.
126. Yuan, X., Li, T., Wang, H., Zhang, T., Barua, M., Borgesi, R.A. et al. (2006) Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells. Am J Pathol 169: 682-696.
127. Zegarra-Moro, O.L., Schmidt, L.J., Huang, H. and Tindall, D.J. (2002) Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 62: 1008-1013.
128. Zheng, K., Yang, F. and Wang, P.J. (2010) Regulation of male fertility by X-linked genes. J Androl 31: 79-85.